- Home
- YI vs NRXP Comparison
YI vs NRXP Comparison
Compare YI & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YI | NRXP |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Retail-Drug Stores and Proprietary Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.0M | 62.2M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | YI | NRXP |
|---|---|---|
| Price | $7.89 | $1.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $30.67 |
| AVG Volume (30 Days) | 31.5K | ★ 516.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $847.91 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.48 | $1.58 |
| 52 Week High | $11.35 | $3.84 |
Technical Indicators
Market Signals| Indicator | YI | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 62.05 | 42.16 |
| Support Level | $6.75 | $1.65 |
| Resistance Level | $8.59 | $2.79 |
| Average True Range (ATR) | 0.37 | 0.11 |
| MACD | -0.15 | 0.02 |
| Stochastic Oscillator | 57.57 | 36.21 |
Price Performance
Historical ComparisonAbout YI 111 Inc.
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.